These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 13998071)

  • 1. [Treatment of the coronary patient with a pyrimido-pyrimidine derivative].
    VUYLSTEEK K; COLLE R; LAURIJSSENS M; VAN DER STRAETEN M
    Belg Tijdschr Geneesk; 1962 Sep; 18():884-99. PubMed ID: 13998071
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical and electrocardiographic observations on the treatment of patients with myocardial infarct and coronary diseases by intravenous infusion of pyrimido-pyrimidine derivative in high doses].
    Cerbella E
    Minerva Cardioangiol; 1969 Sep; 17(9):568-76. PubMed ID: 5398475
    [No Abstract]   [Full Text] [Related]  

  • 3. [THERAPEUTIC ACTION OF A DERIVATIVE OF PYRIMIDO-PYRIMIDINE IN A SIMPLE AND SEDATIVE FORM IN CORONARY INSUFFICIENCY].
    LAI L; COLLICELLI A
    Minerva Cardioangiol; 1964 Feb; 12():83-7. PubMed ID: 14140221
    [No Abstract]   [Full Text] [Related]  

  • 4. [TREATMENT OF CORONARY INSUFFICIENCY WITH 2,6-BIS-DIETHANOLAMINO-4,8-DIPIPERIDINO-PYRIMIDO(5,4-D)PYRIMIDINE].
    DEVEYT F
    Belg Tijdschr Geneesk; 1964 Feb; 20():181-4. PubMed ID: 14139392
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of angina pectoris with a new pyrimido-pyrimidine derivative, Persantin. Clinical experience with the double-blind control technic].
    ROMAN O; SAFFIE F
    Rev Med Chil; 1963 Apr; 91():273-9. PubMed ID: 13982572
    [No Abstract]   [Full Text] [Related]  

  • 6. [OUR CLINICAL EXPERIENCE WITH A NEW SUBSTANCE OF THE PYRIMIDO-PYRIMIDINE GROUP IN THE TREATMENT OF CORONARY (AND CARDIAC) INSUFFICIENCY].
    DIAS FO; FERREIRA FG; NUNES FC; RIOJA DO; SILVA FS
    J Med (Oporto); 1964 Jan; 53():191-6. PubMed ID: 14139582
    [No Abstract]   [Full Text] [Related]  

  • 7. [First results of experimentation with a new coronarodilatory pyrimido-pyrimidine derivative (Ra-8)].
    DE CASTRO B; PARCHI C
    G Clin Med; 1960 Jun; 41():769-810. PubMed ID: 13720442
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of coronary insufficiency with 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)-pyrimidine].
    AGOTE POVEDA IP; VILLANUEVA EDO A; ALONSOLOMAS L; ARIAS MARTINEZ JL; SARRALDE G
    Rev Clin Esp; 1960 Dec; 79():181-9. PubMed ID: 13681671
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies on the syntheses of sulfur containing pyrimido [5,4-d]pyrimidine derivatives. IV. The mechanism of dipyridamole formation from 4,8-dipiperidino-pyrimido [5,4-d]pyrimidine-2,6-disulfonyl dichloride and diethanolamine].
    Imai K; Kojima T; Tamazawa K; Takahashi K; Kawahara S
    Yakugaku Zasshi; 1976 May; 96(5):600-7. PubMed ID: 987191
    [No Abstract]   [Full Text] [Related]  

  • 10. [Microcrystalloscopic and chemical identification of a pyrimido-pyrimidine derivative (persantin)].
    Yalçindağ ON; Onur E
    Turk Hij Tecr Biyol Derg (1961); 1966; 26(2):163-9. PubMed ID: 5963393
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical and cardiographical observations on a derivative of pyrimido-pyrimidine (Persantin)].
    PINO G; ACCATINO G
    Minerva Cardioangiol; 1961 Aug; 9():505-7. PubMed ID: 13735870
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experimental clinical study of the treatment of patients with hearing disorders using 2,6 bis (diethanolamine) 4,8, dipyperidin pyrimido (5,4-D) pyrimidine].
    Bosch Torrent J
    Rev Esp Otoneurooftalmol Neurocir; 1969-1970; 28(165):285-8. PubMed ID: 5397853
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic value of a multiparametric risk score in patients undergoing dipyridamole stress echocardiography.
    Cortigiani L; Bigi R; Gregori D; Sicari R; Picano E
    Am J Cardiol; 2005 Aug; 96(4):529-32. PubMed ID: 16098306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the activity of a pyrimido-pyrimidine derivative in the treatment of coronary insufficiency].
    NIGRO G; D'ALESSANDRO L; COMI LI
    Clin Ter; 1962 Nov; 23():804-14. PubMed ID: 13938596
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole.
    Salcedo J; Kern MJ
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):598-605. PubMed ID: 19496111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease.
    Bodi V; Sanchis J; Lopez-Lereu MP; Nunez J; Mainar L; Monmeneu JV; Husser O; Dominguez E; Chorro FJ; Llacer A
    J Am Coll Cardiol; 2007 Sep; 50(12):1174-9. PubMed ID: 17868810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
    Dieker HJ; French JK; Joziasse IC; Brouwer MA; Elliott J; West TM; Webber BJ; Verheugt FW; White HD
    Am Heart J; 2007 Jan; 153(1):66.e1-8. PubMed ID: 17174639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on the syntheses of sulfur containing pyrimido [5,4-d]pyrimidine derivatives. III. A new synthesis of dipyridamole].
    Imai K; Inukai N; Ishida T; Ozasa T; Kawahara S
    Yakugaku Zasshi; 1976 May; 96(5):593-9. PubMed ID: 987190
    [No Abstract]   [Full Text] [Related]  

  • 19. [5,4-d]pyrimidine].
    BASSO F; BAGNASCO P
    Gazz Med Ital; 1962 Jul; 121():194-201. PubMed ID: 13969899
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging.
    Chow BJ; Wong JW; Yoshinaga K; Ruddy TD; Williams K; deKemp RA; DaSilva J; Beanlands RS
    J Nucl Med; 2005 Jul; 46(7):1095-101. PubMed ID: 16000277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.